The new unit, located in Toronto, will offer the usual range of independent review board (IRB) services as well as a French-speaking support service for clinical programmes conducted in the country.
According to the firm’s website provincial regulations prevent it from providing oversight for research sites in Alberta, Saskatchewan and Newfoundland and Labrador.
In addition, Schulman is not able to review research sites in Nova Scotia that are located in the Capital District Health Authority’s (CDHA) jurisdiction.
